Medically Reviewed by:Dr. Matthew Stanizzi, MD |
Semaglutide and tirzepatide are injectable medications taken once weekly for chronic weight management in eligible adults. While both medications can support weight loss, they work differently, have different FDA-labeled indications, and have shown different average results in major clinical trials.
Semaglutide is a GLP-1 receptor agonist, while Tirzepatide is a dual GIP and GLP-1 receptor agonist.
What's In This Guide
- Semaglutide vs. Tirzepatide at a Glance
- How They Work
- FDA-Approved Uses
- What the Clinical Trials Show
- Side Effects and Safety: Similarities, Differences, and Red Flags
- Practical Considerations People Ask About
- How To Choose the Right Weight Loss Provider in Connecticut
- Frequently Asked Questions (FAQs)
- Bottom Line
Quick Facts
✅ Both are once-weekly injections for chronic weight management in eligible adults.
✅ Tirzepatide targets GIP + GLP-1; semaglutide targets GLP-1.
✅ Trials show higher average weight loss with tirzepatide.
✅ Semaglutide has CV outcomes evidence for certain patients.
✅ Side effects are often GI and dose-related, so titration and follow-up matter.
Semaglutide vs. Tirzepatide at a Glance
| Category | Semaglutide (Wegovy) | Tirzepatide (Zepbound) |
|---|---|---|
| What it is | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Dosing | Once-weekly injection with dose escalation | Once-weekly injection with dose escalation |
| FDA-labeled uses (highlights) | Chronic weight management; CV event risk reduction in adults with established CVD + obesity/overweight | Chronic weight management; moderate to severe OSA in adults with obesity |
| Trial averages for weight loss (major obesity trials) | Mean −14.9% at 68 weeks | Mean about −15.0% to −20.9% at 72 weeks (dose-dependent) |
| Common side effects | Mostly gastrointestinal; often dose-related | Mostly gastrointestinal; often dose-related |
How They Work
GLP-1
GLP-1 receptor agonists influence appetite and fullness signaling and can slow gastric emptying. That often translates to eating less comfortably. Dose escalation is used because gastrointestinal side effects are common, especially early in treatment or after dose increases.
GIP
Tirzepatide also targets GIP receptors, which is one reason it is described as dual agonist. In trials, that dual activity is associated with larger average weight-loss outcomes compared with some single-pathway GLP-1 options, although this is not a guarantee for any individual.
FDA-Approved Uses
Semaglutide (Wegovy) Label Highlights
Wegovy (semaglutide) is a GLP-1 receptor agonist used with a reduced-calorie diet and increased physical activity. It is FDA-indicated for three main uses:
Cardiovascular Risk Reduction (In a Specific Group)
To reduce the risk of major adverse cardiovascular events such as cardiovascular death, non-fatal heart attack, or non-fatal stroke in adults with established cardiovascular disease who also have obesity or are overweight.
Chronic Weight Management
-
- For adults (and pediatric patients ages 12 and up) with obesity
- For adults with overweight who also have at least one weight-related comorbid condition
MASH (Noncirrhotic Liver Disease) Treatment
For the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) (formerly called NASH) with moderate to advanced liver fibrosis, consistent with F2 to F3 fibrosis, in adults.
Tirzepatide (Zepbound) Label Highlights
Zepbound (tirzepatide) is used with a reduced-calorie diet and increased physical activity. It is FDA-indicated for:
Chronic Weight Management
-
- For adults with obesity, or
- For adults with overweight who also have at least one weight-related comorbid condition.
Obstructive Sleep Apnea (OSA)
To treat moderate to severe obstructive sleep apnea in adults with obesity.
What the Clinical Trials Show
Weight Loss in Major Obesity Trials
Semaglutide 2.4 mg (STEP 1)
In adults with overweight or obesity, people taking semaglutide lost an average of 14.9% of body weight over 68 weeks, compared with 2.4% for placebo. Everyone in the study also followed lifestyle changes.
Tirzepatide (SURMOUNT-1)
In adults with overweight or obesity (without type 2 diabetes), average weight loss over 72 weeks was 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg), compared with 3.1% for placebo, alongside lifestyle changes.
What this means for most people:
-
- In these trials, tirzepatide produced greater average weight loss, especially at higher maintenance doses.
- Semaglutide still delivered meaningful average weight loss and has strong evidence across multiple studies, including outcomes data in specific higher-risk groups.
Cardiovascular Outcomes
If you have established cardiovascular disease and meet criteria for overweight or obesity, semaglutide’s cardiovascular outcomes may be especially relevant.
A SELECT trial studied semaglutide in people with overweight or obesity and established cardiovascular disease but without diabetes. It found that semaglutide was associated with a lower risk of major adverse cardiovascular events versus placebo.
Diabetes Context
Some people compare semaglutide and tirzepatide because of type 2 diabetes outcomes, insulin resistance, or A1C goals.
Both medications are also approved in different formulations and doses for type 2 diabetes, and those doses are not the same as the obesity versions. For example:
- Ozempic (semaglutide) is approved for type 2 diabetes.
- Mounjaro (tirzepatide) is approved for type 2 diabetes.
Their labeling, dosing, and indications differ from Wegovy and Zepbound, which are approved for weight management.
Side Effects and Safety: Similarities, Differences, and Red Flags
Common Side Effects (Both)
Typical side effects listed in labeling include:
- Nausea
- Vomiting
- Diarrhea or constipation
- Abdominal pain or discomfort
- Decreased appetite
Practical tolerability tips many clinicians use (individualize to your care plan):
- Eat smaller meals and stop when comfortably full
- Prioritize protein and fiber
- Avoid large, high-fat meals during dose escalation
- Hydrate consistently, especially if nausea limits intake
Boxed Warning and Key Contraindications (Both)
Both products carry a boxed warning related to thyroid C-cell tumors in rodent studies and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
Other Important Safety Considerations
Your prescribing clinician will screen for risks and monitor as appropriate. Label precautions include topics such as:
- Pancreatitis symptoms
- Gallbladder disease
- Acute kidney injury, especially when dehydration occurs from severe GI symptoms
- Hypoglycemia risk when used with certain diabetes medications (varies by regimen)
- Hypersensitivity reactions
Note: Zepbound labeling includes caution related to pulmonary aspiration during general anesthesia or deep sedation. If you are scheduled for a procedure, tell the clinician and anesthesia team that you use a GLP-1 or dual GIP/GLP-1 medication.
When To Contact a Clinician Urgently
Seek medical advice promptly if you have:
- Severe or persistent abdominal pain, especially with vomiting
- Signs of dehydration (dizziness, inability to keep fluids down)
- Symptoms of allergic reaction (hives, swelling, trouble breathing)
- Severe weakness, confusion, or concerning low blood sugar symptoms if you also use glucose-lowering drugs
This list is for general education and is not a substitute for medical advice. If symptoms are severe, rapidly worsening, or you think you may be having an emergency, call a trusted provider.
Practical Considerations People Ask About
Coverage and Access
Insurance coverage for GLP-1 and GIP/GLP-1 medications varies widely. Many plans require prior authorization, which means your clinician may need to document medical necessity and eligibility based on the FDA label.
Even with coverage, out-of-pocket costs can differ depending on deductibles, formularies, and plan rules.
Because availability and coverage policies can change, the most reliable next step is to confirm current benefits directly with your insurer and pharmacy.
Monitoring and Follow-up
A medically supervised approach varies but typically includes:
- A health history review and contraindication screening (including thyroid cancer history and MEN2 risk)
- A plan for dose titration and side-effect management
- Periodic check-ins to assess progress, appetite changes, tolerability, and adherence
- Monitoring of vitals and labs when clinically appropriate, especially if you have diabetes or take other glucose-lowering medications
Other Medications and Interactions
Tell your clinician about all prescription medications, over-the-counter products, and supplements you take. This is especially important if you use insulin or sulfonylureas, since the risk of low blood sugar can increase when combined with certain therapies. Your clinician may adjust dosing or monitoring to improve safety.
Procedures, Sedation, and Travel Planning
If you are scheduled for surgery, endoscopy, or any procedure requiring anesthesia or deep sedation, inform the surgical and anesthesia team that you use a GLP-1 or dual GIP/GLP-1 medication.
Also plan ahead for travel days. Some people feel more nausea during dose changes, so timing and meal planning can help reduce unpleasant surprises.
What Happens if You Stop
Many people need a long-term plan for weight maintenance. If medication is stopped, weight regain is common for some patients, especially if nutrition, activity, sleep, and stress supports are not in place.
The safest approach is to discuss an exit strategy with your clinician, including how you will maintain results and whether another therapy or structured lifestyle plan is appropriate.
How To Choose the Right Weight Loss Provider in Connecticut
Choosing the right provider matters as much as choosing the medication. In Connecticut, look for a clinic that prioritizes medical oversight, safety, and long-term planning.
- Licensed medical supervision: Your care should be directed by a licensed clinician who reviews your full medical history, medications, and contraindications before prescribing.
- Clear eligibility screening: The provider should follow FDA labeling guidelines and assess cardiovascular risk, thyroid history, diabetes status, and other relevant conditions.
- Structured follow-up: Ongoing visits during dose titration and maintenance help manage side effects and improve consistency.
- Transparent medication sourcing: Ask whether the medication is FDA-approved and how it is dispensed.
- Individualized plan: Weight management should include nutrition guidance, lifestyle support, and realistic goal-setting, not just a prescription.
A responsible provider focuses on safety, monitoring, and sustainable progress rather than quick promises or one-size-fits-all programs.
Frequently Asked Questions (FAQs)
How fast do semaglutide or tirzepatide start working?
Many people notice appetite and fullness changes first, sometimes before big changes on the scale. The first few weeks are often about tolerating the medication while the dose is gradually increased. Clinicians typically evaluate meaningful progress over months, alongside nutrition and activity changes.
Can you switch from semaglutide to tirzepatide (or vice versa)?
Yes, in selected patients, but switching should be clinician-directed. The right approach depends on your current dose, side effects, other medications (especially diabetes meds), and why you’re switching. A structured transition can help reduce GI side effects and avoid safety issues.
What if I have GERD or a sensitive stomach?
You may still be a candidate, but pacing matters. Many patients do better with slower titration, smaller meals, and avoiding heavy, high-fat foods around injection days. If reflux or nausea becomes persistent or severe, your clinician may adjust the dose schedule or consider another option.
Do these medications affect oral medications (like birth control)?
They can, especially during dose increases, because GLP-1 effects may slow stomach emptying and potentially change the absorption of some oral drugs. The impact depends on your specific medication and timing. Ask your clinician or pharmacist to review your full medication list before making changes.
What labs or health markers are typically tracked during treatment?
Monitoring is individualized, but often includes weight trends, blood pressure, and waist measurements. Metabolic labs may be checked when clinically appropriate, and A1C or glucose monitoring is more relevant for diabetes or prediabetes.
Bottom Line
Semaglutide and tirzepatide are both evidence-based options for chronic weight management, but the best fit depends on the person. In major obesity trials, tirzepatide showed greater average weight loss, while semaglutide has an FDA-labeled cardiovascular risk-reduction benefit for certain patients and strong long-term clinical data. The right choice comes down to your medical history, goals, tolerability, and FDA eligibility.
If you are in Connecticut and want guidance on whether semaglutide or tirzepatide may be appropriate for you, contact BioRestore to schedule a medical consultation.
DISCLAIMER:
This content is for general educational purposes only and should not be used as medical advice, diagnosis, or treatment guidance. It does not replace an evaluation by a licensed healthcare professional, and it may not apply to your specific health history, medications, or risk factors. Decisions about semaglutide, tirzepatide, dosing, and monitoring should be made with a qualified clinician who can review your full medical profile and provide individualized recommendations. If you develop severe symptoms or think you may be experiencing an emergency, seek urgent medical care.
SOURCES:
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
U.S. Food and Drug Administration. (2025). Wegovy (semaglutide) injection, for subcutaneous use: Highlights of prescribing information (Labeling, NDA 215256, Rev. s024). https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf
U.S. Food and Drug Administration. (2025). Zepbound (tirzepatide) injection, for subcutaneous use: Highlights of prescribing information (Labeling, NDA 217806, Rev. s020). https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2307563
Novo Nordisk, Inc. (2025, January 28). FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [Press release]. PR Newswire. https://www.prnewswire.com/news-releases/fda-approves-ozempic-semaglutide-as-the-only-glp-1-ra-to-reduce-the-risk-of-worsening-kidney-disease-and-cardiovascular-death-in-adults-with-type-2-diabetes-and-chronic-kidney-disease-302362466.html
Farzam, K., & Patel, P. (2024). Tirzepatide. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK585056/